U.S. Congressmen Call On FDA Commissioner To Press Investigation Into Adulterated Heparin During Upcoming Trip To China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Calling the blood thinner heparin that was deliberately adulterated in China and exported to American hospitals the worst drug supply contamination in history, two U.S. congressmen are urging the commissioner of FDA to seek resolution of the case during an upcoming trip to China
You may also be interested in...
Shifting Supply Chain To Asia Will Require More Quality Control Vigilance - World Pharma Manufacturing Summit
SHANGHAI - As Big Pharma continues to shift API manufacturing and contract manufacturing to Asia, it must be vigilant in verifying quality even as regulatory agencies in the region enact more stringent guidelines, according to speakers at the World Pharma Manufacturing Summit in Shanghai
Shifting Supply Chain To Asia Will Require More Quality Control Vigilance - World Pharma Manufacturing Summit
SHANGHAI - As Big Pharma continues to shift API manufacturing and contract manufacturing to Asia, it must be vigilant in verifying quality even as regulatory agencies in the region enact more stringent guidelines, according to speakers at the World Pharma Manufacturing Summit in Shanghai
U.S. Congressional Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not
A U.S. House of Representatives Energy and Commerce Committee investigation into who caused contamination of heparin supplies in 2007 and 2008, how it was done, and U.S. FDA's handling of the crisis, could revive interest in legislation designed to strengthen FDA's oversight of drugs and other medical products entering the U.S. from overseas